Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7685 |
USP25/28 inhibitor AZ1
AZ1 |
DUB | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Ubiquitination |
USP25/28 inhibitor AZ1 (AZ1) 是一种口服有效,选择性,非竞争性的双重泛素特异性蛋白酶 USP25/28抑制,IC50分别为 0.7 μM 和0.6 μM。它有抗炎和抗肿瘤作用。 | |||
T11876 |
LpxH-IN-AZ1
|
Antibacterial | Microbiology/Virology |
LpxH-IN-AZ1 是一种有效的 UDP-2,3-二酰基葡糖胺焦磷酸水解酶LpxH 抑制剂,也是磺酰基哌嗪化合物。LpxH-IN-AZ1 具有抗菌活性,对肺炎克雷伯菌具有抑制作用,IC50 为 0.36 μM。 | |||
T68668 |
AZ-1
|
||
AZ-1 is an inducer of ABCA1 and apoE. It enhances ABCA1 activity and decreases P2X7 receptor activity. AZ-1 activates endogenous LXR signaling but shows no direct LXRα or LXRβ agonist activity. | |||
T26701 |
AZ12216052
AZ 12216052,AZ-12216052 |
||
AZ12216052 is an activator of mGluR II and III. | |||
T14367 |
AZ1495
|
IRAK; CDK; Haspin Kinase | Cell Cycle/Checkpoint; Immunology/Inflammation; NF-κB |
AZ1495 是一种口服有活性的白介素-1受体相关激酶 4(IRAK4)抑制剂,能够作用于 IRAK4 (IC50:5 nM)和 IRAK1 (IC50:23 nM)。可用于研究突变型 MYD88L265P 弥漫性 B 细胞淋巴瘤 (DLBCL) 。 | |||
T26704 |
AZ13705339
AZ-13705339,AZ 13705339 |
PAK | Cytoskeletal Signaling |
AZ13705339 是一种有效的 PAK1 抑制剂,IC50 为 0.33 nM,Kd 为 0.28 nM。 AZ13705339 以 0.32 nM 的 Kd 结合 PAK2。 AZ13705339 可用于癌症研究。 | |||
T6257 |
AZ191
|
DYRK | Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
AZ191 是特异性 DYRK1B 抑制剂。它对 DYRK1B 的特异性分别是 DYRK1A 和 DYRK2 的 5 倍和 110 倍。 | |||
T9650 |
AZ12672857
|
Src; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
AZ12672857 是一种 EphB4 抑制剂,IC50 为 1.3 nM。 AZ12672857 抑制 Src 转染 3T3 细胞的细胞增殖,IC50 为 2 nM,抑制转染 CHO-K1 细胞中 EphB4 的自磷酸化,IC50 为 9 nM。 | |||
T9552 |
BAZ1A-IN-1
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
BAZ1A-IN-1 是BAZ1A(含溴结构域蛋白)抑制剂(Kd:0.52 μM)。它对低表达BAZ1A 的癌细胞表现出弱活性或无活性,但对高表达BAZ1A 的癌细胞系显示出良好的抗生存作用。 | |||
T14366 |
AZ10606120 dihydrochloride
|
P2X Receptor | Membrane transporter/Ion channel; Neuroscience |
AZ10606120 dihydrochloride 是一种可选择的、有效的、高亲和力的受体拮抗剂,在人和大鼠 P2X 7 受体上的 K D 值分别为 1.4 和 19 nM。AZ10606120 dihydrochloride 抑制肿瘤生长,具有抗血管生成活性 。AZ 10606120在与 ATP 结合位点偶联的位点结合时充当负变构调节剂。 | |||
T9461 |
AZ194
|
Sodium Channel | Membrane transporter/Ion channel |
CRMP2-Ubc9-NaV1.7 inhibitor 194 是一流的CRMP2-Ubc9相互作用抑制剂及NaV1.7抑制剂 (IC50=1.2 μM),口服有活性,具有抗伤害作用。AZ194 阻断 CRMP2 的 SUMOylation 以选择性地减少表面表达 NaV1.7 的量。 | |||
T72321 |
AZ13705339 hemihydrate
|
||
AZ13705339 hemihydrate 是一种高效且具有选择性的 PAK1抑制剂,对PAK1和 pPAK1 的IC50分别为 0.33 nM 和 59 nM。AZ13705339 hemihydrate 对PAK1和PAK2具有结合亲和力,Kd 分别为 0.28 nM 和 0.32 nM。AZ13705339 hemihydrate 可用于癌症研究。 | |||
T68693 |
AZ12099548
|
||
AZ12099548 is a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist. | |||
T25123 |
AZ12253801
AZ 12253801,AZ-12253801 |
||
AZ12253801 is a type 1 insulin-like growth factor receptor (IGF-1R) inhibitor. | |||
T30245 |
AZ12441970
AZ-12441970,AZ 12441970 |
||
AZ12441970 is an effective agonist of Toll-like receptor 7 (TLR7 agonist). | |||
T10426 | AZ12601011 | ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
AZ12601011 is a highly potent and selective inhibitor of the TGFBR1 kinase, administered orally. It displays an IC50 of 18 nM and a Kd of 2.9 nM. By selectively targeting ALK4, TGFBR1, and ALK7, AZ12601011 effectively inhibits the phosphorylation of SMAD2. Additionally, it has been shown to hinder the growth and metastasis of mammary tumors [1]. | |||
T18310 |
AZ1508
MC-Lys-MMETA |
Others | Others |
AZ1508, a tubulin inhibitor[1], serves as a drug-linker conjugate for antibody-drug conjugates (ADC) targeting breast and stomach cancer treatment. | |||
T26699 |
AZ10397767
AZ 10397767,AZ-10397767 |
||
AZ10397767 is a potent CXCR2 antagonist (IC50 = 1 nM). AZ10397767 significantly reduced the numbers of infiltrating neutrophils into both in vitro and in vivo tumor models. | |||
T26703 |
AZ13483342
AZ-13483342,AZ 13483342 |
||
AZ13483342 is an antagonist of the melanin concentrating hormone receptor 1 (MCH1) with a potential diabetes therapeutic activity. | |||
T63976 | AZ13824374 | ||
AZ13824374 是高效的、选择性的 ATAD2 抑制剂,对乳腺癌具有抗增殖效果。AZ13824374 在 ATAD2 FRET 和 ATAD2 NanoBRET 检测中对 ATAD2 的pIC50值分别为 8.2 和 6.2。 | |||
T26700 |
AZ11657312 Free Base
AZ-11657312,AZ11657312,AZ 11657312 |
||
AZ11657312 is a P2X7 receptor antagonist. | |||
T70312 |
AZ1366
|
||
AZ1366 is a potent tankyrase inhibitor that enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Combination AZ1366 and irinotecan achieved greater anti-tumor effects compared to monotherapy. Activity was limited to CRC explants that displayed irinotecan resistance and increased protein levels of tankyrase and NuMA. | |||
T26702 |
AZ12971554
AZ 12971554,AZ-12971554 |
||
AZ12971554 is a potent inhibitor of human thrombin. Ki = 0.3nM, Activated partial thromboplastin time (APTT) IC50 = 0.68µM, Ecarin clotting time (ECT) IC50 = 0.16µM in human plasma. | |||
T63968 | AZ14145845 | ||
AZ14145845 是一种具有体内药效的、高度选择性的 I1/2 型 Mer/Axl 双特异性激酶抑制剂。 | |||
T73356 | Ac32Az19 | ||
Ac32Az19 是一种有效、无毒、高选择性的 BCRP 抑制剂,在BCRP 过度表达的HEK293/R2细胞中,EC50值为13 nM。 | |||
T30244 |
AZ12419304
GTPL7734,GTPL 7734,AZ-12419304,GTPL-7734 |
||
AZ12419304, also known as GTPL7734, is a bioactive chemical. |